Company: NDRA
Filing Date: 2025-04-07
Form Type: 10-K/A
Source: 0001654954-25-003937
Chunk: 6

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-04-07
Form: 10-K/A
Chunk 6
---
     |             | -            |   |     |               |     491,924 |   |
| Stock payable towards preference dividend         |     |                      |        - |   |     |        |  - |   |     |                      | - |     |        | - |     |              |       - |     |        |  - |     |                 |       5,233 |     |               | (5,233 | ) |     |             | -            |   |     |               |           - |   |
| Net loss                                          |     |                      |        - |   |     |        |  - |   |     |                      | - |     |        | - |     |              |       - |     |        |  - |     |                 |           - |     |               |      - |   |     |             | (11,507,947  | ) |     |               | (11,507,947 | ) |
| Balance as of December 31, 2024                   |     |                      |   17.488 |   |     | $      |  - |   |     |                      | - |     | $      | - |     |              | 536,908 |     | $      | 53 |     | $               | 105,998,412 |     | $             |      - |   |     | $           | (103,438,099 | ) |     | $             |   2,560,366 |   |

<div align='center'>The accompanying notes are an integral part of these consolidated financial statements.</div>

| F-4 |

<div align='center'>ENDRA Life Sciences Inc.

Consolidated Statements of Cash Flows</div>

|                                                                             | Cash Flows from Operating Activities |   | Year Ended December 31, 2024 |   |     |   | Year Ended December 31, 2023 |   |
|:----------------------------------------------------------------------------|:-------------------------------------|:--|-----------------------------:|:--|:----|:--|-----------------------------:|:--|
| Net loss                                                                    |                                      | $ |                  (11,507,947 | ) |     | $ |                  (10,060,250 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |                                      |   |                              |   |     |   |                              |   |
| Depreciation and amortization                                               |